Drugs / BMS-820132
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01290575 Comparator | Feb → Nov 2011 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01105429 Comparator | May → Oct 2010 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-820132 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01105429 ↗ |
| Route | Oral | “Oral Solution, Oral, 0.3 mg, once daily, 1 day” NCT01105429 ↗ |